Sarasin is to launch an onshore version of its HealthSar Sicav, and has pencilled in an 18 March lau...
Sarasin is to launch an onshore version of its HealthSar Sicav, and has pencilled in an 18 March launch date. HealthSar, which launched in October last year, invests in pharmaceuticals, medical technology and biotechnology on a global basis, in keeping with the company's global themed approach to investing. The fund, which has not yet received FSA approval, will be the fifth fund in Sarasin's onshore Oeic. It will have an up-front charge of 5%, of which 3% is commission, and an annual management charge of 1.5%. It will be marketed exclusively though the intermediary market and have a th...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes